Balance Sheet
Cash Flow Statement
AmortizationOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Asset Writedowns and Impairment (2017 - 2022)

Historic Asset Writedowns and Impairment for RedHill Biopharma (RDHL) over the last 4 years, with Q4 2022 value amounting to $1.5 million.

  • RedHill Biopharma's Asset Writedowns and Impairment fell 8588.05% to $1.5 million in Q4 2022 from the same period last year, while for Dec 2022 it was $6.0 million, marking a year-over-year decrease of 6293.19%. This contributed to the annual value of $6.0 million for FY2022, which is 6293.19% down from last year.
  • As of Q4 2022, RedHill Biopharma's Asset Writedowns and Impairment stood at $1.5 million, which was down 8588.05% from $1.6 million recorded in Q3 2022.
  • RedHill Biopharma's Asset Writedowns and Impairment's 5-year high stood at $10.7 million during Q4 2021, with a 5-year trough of $1.1 million in Q1 2020.
  • Over the past 3 years, RedHill Biopharma's median Asset Writedowns and Impairment value was $1.8 million (recorded in 2020), while the average stood at $2.4 million.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first surged by 41728.45% in 2021, then tumbled by 8588.05% in 2022.
  • RedHill Biopharma's Asset Writedowns and Impairment (Quarter) stood at $2.1 million in 2020, then soared by 417.28% to $10.7 million in 2021, then plummeted by 85.88% to $1.5 million in 2022.
  • Its last three reported values are $1.5 million in Q4 2022, $1.6 million for Q3 2022, and $1.3 million during Q2 2022.